8,456 peer-reviewed studies, each with a short note written from its published abstract: what kind of study it was, who took part, what was measured and what the authors reported. Observational studies show associations, not proof.
People assigned to a diet, food or program and measured.
2019 / Randomized controlled clinical trial
Fifty-five obese women without baseline selenium deficiency were randomly assigned to consume 1 unit/d of Brazil nuts (~1261 μg/Se) or no intervention for 2 months. In the Brazil nut group, all selenium biomarkers and the gene expression of proinflammatory parameters (interleukin-6, tumor necrosis factor-α, and Toll-like receptors 2 and 4) increased significantly (P < 0.05). No changes occurred in the control group. While plasma inflammatory biomarker levels did not change, the authors concluded that the increased gene expression may indicate a proinflammatory stimulus induced by high-selenium Brazil nut consumption in obesity.
Duarte GBS, Reis BZ, Rogero MM, et al. Nutrition, 2019. PMID 31026738
2019 / Inpatient randomized crossover trial
Twenty weight-stable adults were admitted to an inpatient clinical center and randomized to consume ad libitum ultra-processed or unprocessed diets for 2 weeks each in a crossover design, with meals matched for presented calories, energy density, macronutrients, sugar, sodium, and fiber. Energy intake was higher during the ultra-processed diet (508 ± 106 kcal/day; p = 0.0001), driven by increased carbohydrate (280 ± 54 kcal/day; p < 0.0001) and fat (230 ± 53 kcal/day; p = 0.0004), but not protein (-2 ± 12 kcal/day; p = 0.85). Participants gained 0.9 ± 0.3 kg (p = 0.009) during the ultra-processed diet and lost 0.9 ± 0.3 kg (p = 0.007) during the unprocessed diet.
Hall KD, Ayuketah A, Brychta R, et al. Cell Metab, 2019. PMID 31105044
2019 / 8-week randomized, double-blind, placebo-controlled clinical trial
An 8-week randomized, double-blind, placebo-controlled trial evaluated the safety and oral availability of nicotinamide riboside chloride (NIAGEN) in overweight, healthy men and women. Daily consumption of 100, 300, and 1000 mg NR dose-dependently and significantly increased whole blood NAD+ by 22%, 51%, and 142% within 2 weeks, with increases maintained for the remainder of the study. No flushing occurred, and adverse events did not differ significantly between NR and placebo groups or across doses. Additionally, NR did not elevate LDL cholesterol or dysregulate 1-carbon metabolism.
Conze D, Brenner C, Kruger CL Sci Rep, 2019. PMID 31278280
2019 / Pilot study
A pilot study evaluated the postprandial effects of high-fat/high-glycemic load meals enriched with blueberries in 5 obese/overweight patients with metabolic syndrome. Significant decreases in urinary methylamines, acetoacetate, acetone, and succinate were observed at 2 and 4 hours post-ingestion, alongside accumulation of gut-derived phenolic acids. In mononuclear blood cells, mRNA expression of interleukin-6 significantly decreased and transforming growth factor-β significantly increased following blueberry supplementation.
Sobolev AP, Ciampa A, Ingallina C, et al. Metabolites, 2019. PMID 31295937
2019 / 12-week randomized, double-blind, placebo-controlled parallel-group trial
A 12-week randomized, double-blind, placebo-controlled trial evaluated the effects of nicotinamide riboside (NR; 1000 mg twice daily, n = 20) versus placebo (n = 20) in 40 males with obesity and insulin resistance. Supplementation with NR did not affect fasting or postchallenge levels of glucose, insulin, C-peptide, glucagon, GLP-1, or GIP, and β-cell function did not respond to the intervention. Furthermore, no changes in circulating adipsin or bile acids were observed.
Dollerup OL, Trammell SAJ, Hartmann B, et al. J Clin Endocrinol Metab, 2019. PMID 31390002
2019 / Randomized, double-blind, placebo-controlled pilot study
A randomized, double-blind, placebo-controlled pilot study evaluated 60 overweight adults with symptomatic knee osteoarthritis assigned to 600 mg of non-animal chondroitin sulfate (CS) daily or placebo for 12 weeks. The experimental group showed a significant increase in Tegner Lysholm Knee Scoring (+10.64 points; 95% CI 5.57, 15.70; p < 0.01) and a decrease in WOMAC score (-12.24 points; 95% CI -16.01, -8.38; p < 0.01). Significant decreases were also seen in C-reactive protein (-0.14 mg/dL; 95% CI -0.26, -0.04; p < 0.01), erythrocyte sedimentation rate (-5.01 mm/h; 95% CI -9.18, -0.84; p < 0.01), and visual analogue scale pain scores in both knees.
Rondanelli M, Braschi V, Gasparri C, et al. Nutrients, 2019. PMID 31470599
2019 / Single-arm pre-post intervention study
Researchers evaluated an 8-week group program utilizing an ad-libitum whole-food plant-based dietary pattern in 79 self-referred participants, with 78 completing. Completers achieved an average weight loss of 5.5 ± 3.0 kg (p < 0.0001), with larger percentage losses in those with higher baseline BMI. Systolic blood pressure decreased by 7.1 ± 15.5 mmHg (p = 0.0002), diastolic blood pressure decreased by 7.3 ± 10.9 mmHg (p < 0.0001), total cholesterol decreased by 25.2 ± 24.7 mg/dL (p < 0.0001), and LDL decreased by 15.3 ± 21.1 mg/dL (p < 0.0001). Additionally, 21 participants (26.9%) decreased or stopped at least one chronic medication.
Campbell EK, Fidahusain M, Campbell Ii TM Nutrients, 2019. PMID 31484341
2019 / Prospective intervention study with a matched control group
Researchers compared 27 overweight/obese women with PCOS to 25 matched controls after a 3-day standardized diet, followed by a 3-month oral contraceptive (OC) intervention with dietary advice in the PCOS group. At baseline, the PCOS group showed significantly higher serum levels of TMAO, choline, betaine, and carnitine, with TMAO and choline correlating with total testosterone. Following the 3-month OC therapy and lifestyle intervention, TMAO and its precursors significantly decreased alongside reductions in BMI, total testosterone, and free androgen index.
Eyupoglu ND, Caliskan Guzelce E, Acikgoz A, et al. Clin Endocrinol (Oxf), 2019. PMID 31556132
2019 / Randomized controlled trial
Thirty adult men completed a 24-hour water-only fast on the same day of the week for three subsequent weeks, receiving placebo or a bitter hops-based appetite suppressant (Amarasate) at high (250 mg) or low (100 mg) doses at 16 and 20 hours into the fast. From 18 to 24 hours of the fast, both high- and low-dose groups had a statistically significant (p < 0.05) greater than 10% reduction in hunger compared with placebo. Furthermore, the expected lunchtime rise in hunger seen at 12:00 h in the placebo group was absent in both hops extract treatment groups.
Walker E, Lo K, Tham S, et al. Nutrients, 2019. PMID 31766216
2019 / Randomized controlled trial
In a randomized trial, 70 healthy Japanese adults with a BMI between 23 and 30 consumed 9 grams daily of either quercetin-rich onion powder or placebo for 12 weeks. Visceral fat area did not differ significantly between the groups overall, though it was lower with onion powder in participants with low HDL cholesterol. Alanine aminotransferase levels were also significantly reduced in the onion powder arm compared to placebo.
Nishimura M, Muro T, Kobori M, et al. Nutrients, 2019. PMID 31905615
2018 / Randomized controlled pilot trial
Twenty-four obese male veterans were randomized to either a 5:2 intermittent energy-restricted diet or a standard daily energy-restricted diet for 6 months. Mean weight loss was 5.3 ± 3.0 kg (5.5 ± 3.2%) with the 5:2 diet and 5.5 ± 4.3 kg (5.4 ± 4.2%) with standard restriction, with no significant differences between groups for weight or waist reduction. Systolic blood pressure decreased in both groups, but neither regimen significantly shifted diastolic pressure, fasting glucose, or blood lipids.
Conley M, Le Fevre L, Haywood C, et al. Nutr Diet, 2018. PMID 28791787
2018 / 2-year prospective randomized trial
In a 2-year randomized trial, 70 healthy postmenopausal overweight or obese women were assigned to a Paleolithic-type diet (PD, n=35) or a diet based on Nordic Nutrition Recommendations (NNR, n=35). At baseline, median 24-h urinary iodine concentration (24-UIC, 71.0 μg/l) and excretion (24-UIE, 134.0 μg/d) were similar between groups. After 6 months, 24-UIC fell to 36.0 μg/l (P=0.001) and 24-UIE dropped to 77.0 μg/d (P=0.001) in the PD group, while levels remained unaltered in the NNR group. Free thyroxin, TSH, and free triiodothyronine (FT3) were generally similar between groups, though FT3 was lower in the PD group at 6 months.
Manousou S, Stål M, Larsson C, et al. Eur J Clin Nutr, 2018. PMID 28901333
2018 / Controlled trial
Participants (n = 51) were provided an 825-calorie lunch eaten either while listening to an audio clip prompting focus on sensory properties of food or in silence, followed by a snack offered 2 hours later. While lunch intake did not differ significantly between groups, the mindful eating group consumed significantly fewer snack calories than controls (mean = 112.30 calories, SD = 70.24 vs. mean = 203.20 calories, SD = 88.05; Cohen's d = 1.14). This effect was not explained by enhanced memory for lunch and occurred regardless of gender or interoceptive awareness, with no significant moderation by reward sensitivity.
Seguias L, Tapper K Appetite, 2018. PMID 29104106
2018 / Randomized crossover trial
Eighteen healthy volunteers completed two study visits following an overnight fast, receiving tablets containing either 6845 mg sodium propionate or 4164 mg sodium chloride over 180 minutes in random order. REE and substrate oxidation were measured by indirect calorimetry. Oral sodium propionate administration significantly increased REE (0.045 ± 0.020 kcal/min; P = .036) and whole-body lipid oxidation (0.012 ± 0.006 g/min; P = .048), independent of glucose and insulin changes.
Chambers ES, Byrne CS, Aspey K, et al. Diabetes Obes Metab, 2018. PMID 29134744
2018 / Randomized controlled trial
In an ancillary randomized controlled trial of 53 healthy nonobese adults, 24 months of caloric restriction decreased body weight by 9 ± 0.5 kg, visceral adipose tissue by 0.5 ± 0.01 kg, and blood pressure (systolic -8 ± 3 mmHg; diastolic -6 ± 2 mmHg) compared to ad libitum eating. Total cholesterol fell by 13.6 ± 5.3 mg/dl, LDL-cholesterol decreased by 12.9 ± 4.4 mg/dl, and estimated 10-year cardiovascular risk dropped by 30%. Insulin resistance initially improved during weight loss, but this change was not maintained during weight maintenance.
Most J, Gilmore LA, Smith SR, et al. Am J Physiol Endocrinol Metab, 2018. PMID 29351490
2018 / Secondary analysis of a randomized controlled trial
Thirty-four obese participants completed 12 months of alternate-day fasting and were categorized by achieving at least 5% weight loss or under 5% weight loss. The high-loss group experienced increased fullness (p = 0.04) and decreased hunger (p = 0.03). They also raised dietary protein from 15% to 20% of energy intake (p = 0.04) and adhered more closely to fast-day caloric targets.
Kroeger CM, Trepanowski JF, Klempel MC, et al. Nutr Health, 2018. PMID 29353535
2018 / Parallel-design randomized controlled trial
Forty-two normal-weight healthy short sleepers were randomized to a sleep extension group receiving a sleep hygiene behavioral consultation (n = 21) or a control group maintaining habitual short sleep (n = 21) for 4 weeks. Compared with controls, the sleep extension group significantly increased time in bed (0:55 h:mm), sleep period (0:47 h:mm), and sleep duration (0:21 h:mm). Sleep extension led to a significant reduction in free sugar intake (-9.6 g vs. 0.7 g in controls; P = 0.042), with no significant differences observed between groups in markers of energy balance or cardiometabolic health.
Al Khatib HK, Hall WL, Creedon A, et al. Am J Clin Nutr, 2018. PMID 29381788
2018 / Randomized controlled trial
A randomized, double-blind, placebo-controlled trial evaluated d-allulose at 4 g or 7 g twice daily against sucralose in 121 Korean adults with BMI ≥ 23 kg/m². Body fat percentage and body fat mass decreased following allulose supplementation. Compared with placebo, the high-dose group demonstrated significant reductions in BMI along with total abdominal and subcutaneous fat areas on CT scans, with no differences in lipid profiles or nutrient intake.
Han Y, Kwon EY, Yu MK, et al. Nutrients, 2018. PMID 29385054
2018 / Open-label, non-randomized, controlled study
An open-label, non-randomized controlled study evaluated a 1-year continuous care intervention (CCI) delivering remote care, biometric feedback, and nutritional ketosis versus usual care (UC) in adults with type 2 diabetes. In the CCI group, HbA1c declined from 7.6 ± 0.09% to 6.3 ± 0.07%, weight decreased by 13.8 ± 0.71 kg, and non-metformin diabetes medication prescriptions fell from 56.9 ± 3.1% to 29.7 ± 3.0% (all P < 1.0 × 10^-16). Insulin was reduced or stopped in 94% of users, sulfonylureas were eliminated, and improvements were observed in HOMA-IR, hsCRP, and triglycerides, alongside a 10% increase in LDL-C; usual care participants had no significant biomarker or medication changes.
Hallberg SJ, McKenzie AL, Williams PT, et al. Diabetes Ther, 2018. PMID 29417495
2018 / Randomized controlled trial
Overweight or obese adults were randomized to an 8-week caloric restriction diet alone (CR, n = 15) or combined with sleep restriction on 5 nights per week (CR + SR, n = 21). Both groups had similar total weight, lean mass, and fat mass loss. However, the proportion of total mass lost as fat was significantly greater in the CR group (p = 0.016). Resting respiratory quotient decreased only in CR (p = 0.033), and fasting leptin concentration decreased only in CR + SR (p = 0.029).
Wang X, Sparks JR, Bowyer KP, et al. Sleep, 2018. PMID 29438540
2018 / Repeated-measures test-retest trial
Eleven participants completed two 24-hour fasts following a 3-day standardized weight-maintenance diet to evaluate test-retest reliability of hunger variables and subsequent energy intake. At 16 hours of fasting, ICCs for all hunger-related assessments were significant (r = 0.67-0.91; p ≤ 0.05), but reliability varied over time, with average ICCs of 0.81 for fullness, 0.74 for prospective food consumption (PFC), 0.67 for energy, 0.44 for desire to eat (DTE), and 0.36 for hunger. Average post-fast energy compensation was 60% of weight-maintenance needs (ranging 7 to 110%) and correlated with changes in PFC, hunger, and DTE, but not body fat percentage. After fasting, percent energy intake from fat and protein increased (29.9% to 37.3% and 13.8% to 16.8%), while carbohydrate intake decreased (56.4% to 46.0%).
Tinsley GM, Moore ML, Graybeal AJ Physiol Behav, 2018. PMID 29438660
2018 / Randomized controlled pilot study
An 8-week randomized controlled pilot study examined the impact of energy distribution timing within a hypocaloric, three-meal diet in 8 participants. Participants were assigned to either a Morning pattern (50%, 30%, and 20% of kcal at breakfast, lunch, and dinner) or an Evening pattern (20%, 30%, and 50% of kcal at breakfast, lunch, and dinner). Percent weight loss and regularity of sleep onset and wake times were significantly greater for Morning compared to Evening (p < 0.05). The authors note the need for longer studies in free-living participants with time-stamped dietary assessments.
Raynor HA, Li F, Cardoso C Physiol Behav, 2018. PMID 29471076
2018 / Randomized trial
Twenty-seven overweight or obese adults were randomized to intermittent energy restriction (IER, n=15) or continuous energy restriction (CER) until achieving 5% weight loss, followed by 7 days of weight stabilization. There was no significant difference in time to 5% weight loss (median 59 d vs 73 d, P=0.246) or body composition changes between groups. Neither diet significantly altered postprandial glycaemia (P=0.266), and insulinaemia was reduced comparatively (P=0.903). However, IER led to a significantly greater relative reduction in postprandial TAG responses (106 to 68 mmol×360 min/l) compared to CER (117 to 130 mmol×360 min/l; P=0.045), and a trend toward a greater reduction in C-peptide (P=0.057).
Antoni R, Johnston KL, Collins AL, et al. Br J Nutr, 2018. PMID 29508693
2018 / Randomized clinical trial (2x2 factorial)
A 2x2 factorial randomized trial assigned 92 functionally limited older men for 6 months to controlled diets of 0.8 or 1.3 g/kg/d of protein, paired with weekly testosterone or placebo. Changes in lean body mass (0.31 kg; 95% CI, -0.46 to 1.08 kg; P = .43), appendicular lean mass, muscle strength, physical function, and well-being did not differ between protein levels, regardless of testosterone use. However, fat mass decreased significantly more with higher protein intake compared to the RDA group (difference, -1.12 kg; 95% CI, -2.04 to -0.21; P = .02).
Bhasin S, Apovian CM, Travison TG, et al. JAMA Intern Med, 2018. PMID 29532075